Osteoclasts differential-related prognostic biomarker for osteosarcoma based on single cell, bulk cell and gene expression datasets

BMC Cancer. 2022 Mar 17;22(1):288. doi: 10.1186/s12885-022-09380-z.

Abstract

Osteosarcoma (OS) is one of the most common primary bone malignant tumors. Osteoclasts have been shown to have a valuable role in OS. In the present study, we analyzed the differentiation states of osteoclasts in OS and their prognostic significance based on integrated scRNA-seq and bulk RNA-seq data. Osteoclasts in distinct differentiation states were characterized, and 661 osteoclasts differentiation-related genes (ODRGs) were obtained. ORDGs in distinct differentiation states were enriched in distinct functions and pathways. TPM1, S100A13, LOXL1, PSMD10, ST3GAL4, PEF1, SERPINE2, TUBB, FAM207A, TUBA1A, and DCN were identified as the significant survival-predicting ODRGs. We successfully developed a risk score model based on these survival-predicting ODRGs. In addition, we generated a nomogram applicable for clinical with both ODRGs signatures and clinicopathological parameters, and validated in OS cohorts to predict OS patient outcome. This study proposed and verified the important roles of osteoclasts differentiation in the prognosis of patients with OS, suggesting promising therapeutic targets for OS.

Keywords: Differentiation; Osteoclasts; Osteosarcoma; Prognostic; scRNA-seq.

MeSH terms

  • Adolescent
  • Biomarkers, Tumor / genetics*
  • Bone Neoplasms / genetics*
  • Bone Neoplasms / pathology
  • Cell Differentiation / genetics*
  • Female
  • Gene Expression Profiling
  • Humans
  • Male
  • Osteoclasts / cytology*
  • Osteoclasts / pathology
  • Osteosarcoma / genetics*
  • Osteosarcoma / pathology
  • Prognosis
  • Proportional Hazards Models
  • RNA-Seq
  • Risk Factors
  • Single-Cell Analysis
  • Young Adult

Substances

  • Biomarkers, Tumor